JPH024279B2 - - Google Patents
Info
- Publication number
- JPH024279B2 JPH024279B2 JP4239482A JP4239482A JPH024279B2 JP H024279 B2 JPH024279 B2 JP H024279B2 JP 4239482 A JP4239482 A JP 4239482A JP 4239482 A JP4239482 A JP 4239482A JP H024279 B2 JPH024279 B2 JP H024279B2
- Authority
- JP
- Japan
- Prior art keywords
- thymolphthalein
- substrate
- present
- alkaline phosphatase
- measurement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 claims description 36
- 239000000758 substrate Substances 0.000 claims description 19
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 15
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 15
- 239000000872 buffer Substances 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- LDKDGDIWEUUXSH-UHFFFAOYSA-N Thymophthalein Chemical compound C1=C(O)C(C(C)C)=CC(C2(C3=CC=CC=C3C(=O)O2)C=2C(=CC(O)=C(C(C)C)C=2)C)=C1C LDKDGDIWEUUXSH-UHFFFAOYSA-N 0.000 claims description 10
- JWBPMLSZYOGYFD-UHFFFAOYSA-N [4-[1-(4-hydroxy-2-methyl-5-propan-2-ylphenyl)-3-oxo-2-benzofuran-1-yl]-5-methyl-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(O)C(C(C)C)=CC(C2(C3=CC=CC=C3C(=O)O2)C=2C(=CC(OP(O)(O)=O)=C(C(C)C)C=2)C)=C1C JWBPMLSZYOGYFD-UHFFFAOYSA-N 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 7
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 6
- 238000002835 absorbance Methods 0.000 claims description 5
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 238000005259 measurement Methods 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000000691 measurement method Methods 0.000 description 6
- 239000012086 standard solution Substances 0.000 description 6
- 239000012089 stop solution Substances 0.000 description 6
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 238000003748 differential diagnosis Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- ANAZDOWEOOFEET-UHFFFAOYSA-N (4-hydroxyphenyl) [4-(3-oxo-1h-2-benzofuran-1-yl)phenyl] hydrogen phosphate Chemical compound C1=CC(O)=CC=C1OP(O)(=O)OC1=CC=C(C2C3=CC=CC=C3C(=O)O2)C=C1 ANAZDOWEOOFEET-UHFFFAOYSA-N 0.000 description 1
- 208000015163 Biliary Tract disease Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000000741 bile canaliculi Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4239482A JPS58158199A (ja) | 1982-03-17 | 1982-03-17 | 血清アルカリ性ホスフアタ−ゼ活性測定方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4239482A JPS58158199A (ja) | 1982-03-17 | 1982-03-17 | 血清アルカリ性ホスフアタ−ゼ活性測定方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58158199A JPS58158199A (ja) | 1983-09-20 |
| JPH024279B2 true JPH024279B2 (enExample) | 1990-01-26 |
Family
ID=12634843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4239482A Granted JPS58158199A (ja) | 1982-03-17 | 1982-03-17 | 血清アルカリ性ホスフアタ−ゼ活性測定方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58158199A (enExample) |
-
1982
- 1982-03-17 JP JP4239482A patent/JPS58158199A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58158199A (ja) | 1983-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9145576B2 (en) | Device and method for detection of humidity-compromised urine test strips | |
| US3485587A (en) | Protein indicator | |
| Burch et al. | Improved method for measurement of delta-aminolevulinic acid dehydratase activity of human erythrocytes | |
| Carroll et al. | A simplified alkaline phosphotungstate assay for uric acid in serum | |
| US4101382A (en) | Novel reagent and method for the determination of urea in biological fluids | |
| Panteghini et al. | Measurement of pancreatic lipase activity in serum by a kinetic colorimetric assay using a new chromogenic substrate | |
| CN105388146B (zh) | 一种同时检测尿液中钠、肌酐和微量白蛋白的试剂盒 | |
| Orsonneau et al. | Simple and sensitive determination of urea in serum and urine | |
| US5055407A (en) | Composition and method of assaying aqueous liquids for specific gravity | |
| JPH05503997A (ja) | グルコース測定用の対照試薬 | |
| US3934977A (en) | Reagent and method for determining total calcium in body fluids | |
| US3878048A (en) | Determination of gamma-glutamyl transpeptidase in biological fluids and diagnostic reagents used therefor | |
| US3888739A (en) | Reagents and methods for determining amylase concentrations | |
| Cornish et al. | An automated fluorometric alkaline phosphatase microassay with 4-methylumbelliferyl phosphate as a substrate | |
| Ludvigsen et al. | Kinetic enzymic assay for D (-)-lactate, with use of a centrifugal analyzer. | |
| JPH024279B2 (enExample) | ||
| Ewen et al. | Improved determination of prostatic acid phosphatase (sodium thymolphthalein monophosphate substrate). | |
| Asp | Improved method for the assay of phenylglycosidase activity with a 4-aminoantipyrine reagent | |
| US5874229A (en) | Method for avoiding influence of hemoglobin | |
| US4096037A (en) | Arginase test | |
| CA1184101A (en) | Determination of lecithin | |
| JP2002238598A (ja) | カルシウムイオン測定用組成物および測定方法 | |
| Rietz et al. | Fluorometric method for measuring serum lipase activity | |
| EP0335136B1 (en) | Calcium assay reagent | |
| Yoshikazu et al. | A simple and rapid microdiffusion method for blood ammonia using a reflectance meter and a reagent plate, and its clinical evaluation for liver diseases |